EURid Reveals Slovenia as the Top Country for Registration Growth in its Q2 2020 Progress Report
18.8.2020 12:30:00 EEST | Business Wire | Press release
EURid released its Q2 2020 Progress Report today, sharing its quarterly statistics and developments. Highlights include:
- 163 277 new domain name registrations recorded;
- Slovenia tops the list of countries for registration growth at +4.8%;
- The average renewal rate was 83.9%
Total registrations decreased from 3 623 050 at the end of Q1 2020 to 3 606 143 at the end of Q2 2020. This can be attributed to a higher rate of deletions among UK-based registrations in light of the .eu registrations update relating to Brexit.
Main developments throughout the quarter included:
- Kick-off of the 7th annual .eu Web Awards competition;
- Partnership with the Coordination Center for TLD .RU/.РФ for the annual EURid UNESCO World Report on IDNs;
- Strengthening our collaboration with the EUIPO and Ecommerce Foundation to benefit SMEs and .eu online stores;
- Brexit update regarding .eu domain names registered to individuals and undertakings residing in the United Kingdom and Gibraltar: the Withdrawal Agreement between the UK and EU provides a transition period until 31 December 2020; as of 1 January 2021, 00:00:00 CET , EURid will no longer allow the registration of any new domain names by UK registrants.
- Supporting the ‘Water is Life’ project in Madagascar to offset our 2019 CO2 emissions.
Read more from EURid’s Q2 2020 Progress Report.
About EURid
EURid is the not-for-profit organisation that operates the .eu, .ею and .ευ top-level domains, following a tender process and appointment by the European Commission. EURid works with over 700 accredited registrars. As part of its ongoing commitment to data security, EURid has been certified for the ISO27001 security standard since 2013. EURid is also registered by the EU Eco-Management and Audit Scheme (EMAS), which is an expression of its environmental commitment. EURid has its headquarters in Diegem (Belgium), and regional offices in Pisa (Italy), Prague (the Czech Republic) and Stockholm (Sweden). More information at: www.eurid.eu.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200818005375/en/
Contact information
EURid
Reelika Kirna
press@eurid.eu
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
KfW, Germany’s largest national promotional bank, future-proofs regulatory reporting, by migrating to Regnology Reporting Hub (RRH)19.5.2026 09:33:00 EEST | Press release
Regnology, a leading provider at the intersection of regulatory, risk, and supervisory technology, today announced that KfW Bankengruppe (KfW) is advancing its long-term partnership with the company by electing to migrate to the next-generation Regulatory Reporting Hub (RRH). The solution will be delivered as a cloud-native service on Rcloud, Regnology’s high-performance cloud architecture layer. This strategic move to the modern RRH platform future-proofs the mission-critical reporting functions for one of the world's leading promotional banks. Headquartered in Frankfurt am Main, KfW is a public‑law institution dedicated to supporting sustainable economic, social and ecological development in Germany, across Europe and globally. Regnology’s foresight led to the 2023 launch of Rcloud, its state-of-the-art architecture layer built on Google Cloud, enabling next‑generation solutions like RRH to operate with the full power of cloud-native design delivering the clear operational and strate
ATB Therapeutics Appoints Mark Throsby as CEO to Lead Next Phase of Growth19.5.2026 09:00:00 EEST | Press release
ATB Therapeutics (“ATB” or the “Company”), a biopharmaceutical company advancing next-generation antibody-based therapies for oncology and immunology, today announced the appointment of Mark Throsby, PhD, as Chief Executive Officer. The leadership transition marks an important milestone as the Company continues its evolution from a startup into a development-stage biopharmaceutical company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260513198633/en/ ATB Therapeutics Appoints Mark Throsby as CEO to Lead Next Phase of Growth Mark Throsby has served as Executive Chairman and Chief Scientific Officer since 2024, during which time he supported the Company’s growth, including the successful closing of its Series A financing, the expansion of the scientific team, and the advancement of its therapeutic programs. In his new role, he will lead ATB’s strategy and senior leadership team as the Company prepares to enter clinical deve
TREASoURcE Shows How Circular Economy Solutions Can Move Beyond Pilots Across Sectors and Regions19.5.2026 08:00:00 EEST | Press release
Across Europe, many circular economy solutions struggle to move beyond isolated pilots and into real-world deployment at scale. New approaches are needed that combine technical feasibility, market relevance and citizen engagement, while remaining adaptable to local contexts. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260518914041/en/ TREASoURcE addressed circular economy challenges across energy, plastics and biobased side streams, combining technical solutions with stakeholder and citizen engagement. The EU-funded TREASoURcE project provides evidence that systemic, citizen-engaged circular economy solutions can be developed, tested and prepared for replication across regions. Using a common regional approach, the project combined real-life demonstrations, cross-value chain collaboration and early consideration of transferability to translate circular economy concepts into practical solutions in the fields of energy, mat
Shufti Recognised as Dual Leader in Liminal's 2026 Age Verification and Age Estimation Indexes, with Exceptional Ratings Across Both Benchmarks19.5.2026 08:00:00 EEST | Press release
Shufti has been named a Leader in both the Age Verification and Age Estimation categories of Liminal’s 2026 Index Report, receiving an Exceptional rating for Market Presence across both. Liminal, an actionable intelligence firm, evaluates identity verification vendors across Product Execution, Strategy, and Market Presence, assessing scalability, accuracy, fraud resistance, innovation, and user experience. Out of 189 vendors assessed in the Age Verification Index, only 17 achieved Leader status. Shufti was among them and exceeded the leadership threshold with a 64% Product Execution score and a 92% Strategy score. In Age Estimation, Shufti again ranked among 17 Leaders from 80 evaluated vendors, exceeding leadership thresholds across core evaluation pillars, alongside an Exceptional Market Presence rating in both categories. “Achieving Leader status in both Age Estimation and Age Verification reflects that our solutions are built for accurate, scalable, and privacy-first age assurance
Azafaros Strengthens Leadership Team With Appointment of Amy Sullivan as Chief Financial Officer19.5.2026 08:00:00 EEST | Press release
Azafaros, a private company building a portfolio to become a leader in Lysosomal Storage Disorders and focused on addressing neurological symptoms, today announced that Amy Sullivan has joined the company as Chief Financial Officer. Ms. Sullivan brings more than 30 years’ experience in the life sciences sector, with expertise in capital raising, corporate strategy and communications. She joins Azafaros from IO Biotech, where she served as Chief Financial Officer. “Amy is a highly accomplished financial leader with a strong track record of supporting growth-stage biotech companies,” said Stefano Portolano, Chief Executive Officer at Azafaros. “Her expertise in financing, strategic positioning and transaction execution will be instrumental as we advance our Phase 3 studies with nizubaglustat and continue to build Azafaros as we prepare to file for drug marketing authorization and launch in GM1/GM2 and NPC.” “I am excited to join Azafaros at such an important stage in the company’s develo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom